Table II.
The number of Trp53+/– mice developing tumours was 30% fewer in supplemented animals
Untreated Supplemented % Difference Chi-square Number % Number % Mice affected by tumoursa 34/41 83 26/45 58 30 P = 0.018 Observed tumour types Sarcoma 19/38 50 17/43 40 20 P = 0.378 Osteosarcoma 13/38 34 8/43 19 44 P = 0.132 Soft-tissue sarcoma 6/38 16 7/43 16 – P > 0.05 Astrosarcoma 0/38 0 1/43 2 – P > 0.05 Chondrosarcoma 0/38 0 1/43 2 – P > 0.05 Carcinoma 16/38 42 6/43 14 67 P = 0.006 Adenocarcinoma 14/38 37 6/43 14 62 P = 0.021 Basosquamous carcinoma 2/38 5 0/43 0 – P = 0.217 Lymphoma 9/38 24 5/43 12 50 P = 0.239 Pheochromocytoma 2/38 5 0/43 0 – P = 0.217 Multiple tumour burdenb 13/38 34 4/43 9 74 P = 0.012 Metastasis 7/38 18 0/43 0 100 P = 0.004 Types of tumours observed and their frequencies are compared in the table. Significant probabilities for DSP impacts are bolded.
aTotal tumour burden includes thee untreated mice and two treated mice that were not submitted for complete biopsy but that had large abdominal tumours characteristic of soft-tissue sarcomas. Only mice that had complete necropsy reports were included in the analysis of tumour types. If the five tumour mice are excluded from the total cancer comparison, the percent reduction in cancer by the supplement becomes 32% (P < 0.0096).
bNumber of mice diagnosed with two or three different primary types of tumours.